S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
S&P 500   4,273.79 (-0.20%)
DOW   33,562.86 (-0.59%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Forecast, Price & News

$23.23
-0.03 (-0.13%)
(As of 06/5/2023 ET)
Compare
Today's Range
$22.84
$23.33
50-Day Range
$21.63
$25.15
52-Week Range
$17.86
$30.14
Volume
470,938 shs
Average Volume
770,565 shs
Market Capitalization
$2.36 billion
P/E Ratio
28.33
Dividend Yield
N/A
Price Target
$26.71

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
15.0% Upside
$26.71 Price Target
Short Interest
Bearish
19.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.98
Upright™ Environmental Score
News Sentiment
0.24mentions of Corcept Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$716,100 Sold Last Quarter
Proj. Earnings Growth
-1.61%
From $0.62 to $0.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

560th out of 985 stocks

Pharmaceutical Preparations Industry

270th out of 486 stocks


CORT stock logo

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Corcept Therapeutics (NASDAQ: CORT)
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
Corcept Therapeutics (NASDAQ:CORT) Shares Down 2.7%
Corcept Therapeutics (NASDAQ:CORT) Now Covered by SVB Leerink
See More Headlines

CORT Price History

CORT Company Calendar

Last Earnings
5/03/2023
Today
6/05/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
238
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$26.71
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+14.9%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$101.42 million
Pretax Margin
26.04%

Debt

Sales & Book Value

Annual Sales
$401.86 million
Cash Flow
$0.97 per share
Book Value
$4.66 per share

Miscellaneous

Free Float
82,686,000
Market Cap
$2.36 billion
Optionable
Optionable
Beta
0.50

Social Links


Key Executives

  • Joseph K. Belanoff
    President, Chief Executive Officer & Director
  • Atabak Mokari
    Chief Financial Officer
  • Hazel Hunt
    Chief Scientific Officer
  • Sean MaduckSean Maduck
    President-Corcept Endocrinology
  • William Guyer
    Chief Development Officer













CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CORT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CORT, but not buy additional shares or sell existing shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 1-year target prices for Corcept Therapeutics' stock. Their CORT share price forecasts range from $22.00 to $32.00. On average, they predict the company's share price to reach $26.71 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2023?

Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 14.4% and is now trading at $23.24.
View the best growth stocks for 2023 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings results on Wednesday, May, 3rd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biotechnology company had revenue of $105.70 million for the quarter, compared to analysts' expectations of $104.91 million. Corcept Therapeutics had a trailing twelve-month return on equity of 19.37% and a net margin of 22.79%. The company's revenue was up 12.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.20 EPS.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435.00 million-$455.00 million, compared to the consensus revenue estimate of $435.73 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.88%), Ingalls & Snyder LLC (8.24%), Renaissance Technologies LLC (6.68%), State Street Corp (3.24%), Federated Hermes Inc. (2.72%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $23.24.

How much money does Corcept Therapeutics make?

Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.36 billion and generates $401.86 million in revenue each year. The biotechnology company earns $101.42 million in net income (profit) each year or $0.82 on an earnings per share basis.

How many employees does Corcept Therapeutics have?

The company employs 238 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -